Abstracts tagged "Malignancy and rheumatoid arthritis (RA)"

Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting
The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Katherine Larson¹, Faizah Siddique² and Samya Mohammad¹, ¹Virginia Commonwealth University, Richmond, VA, ²Department of Veterans Affairs, Richmond, VA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…
Abstract Number: 1510 • 2016 ACR/ARHP Annual Meeting
Trends in the Occurrence of Malignancy in Japanese Patients with Rheumatoid Arthritis Based on the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort during a 14-Year Observation Period
Naoki Sugimoto, Eiichi Tanaka, Eisuke Inoue, Moeko Ochiai, Yoko Shimizu, Rei Yamaguchi, Kumi Shidara, Ayako Nakajima, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Along with increased proportions of patients using methotrexate (MTX) and biological agents (from 34.2% and 0.0% in 2000 to 77.3% and 18.8% in 2013,…
Abstract Number: 2052 • 2015 ACR/ARHP Annual Meeting
Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes
Karin Hellgren¹, Christer Sundström², Johan Askling³, Eva Baecklund⁴ and on behalf of the ARTIS study group, ¹Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden, ²Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden, ³Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden
Background/Purpose: The long-term lymphoma risk in patients with rheumatoid arthritis (RA) treated with biologic disease modifying anti-rheumatic drugs (bDMARDs) remains a concern. The aim of…
Abstract Number: 1514 • 2015 ACR/ARHP Annual Meeting
Incidence and Risk Factors of Malignancy in a Cohort of Rheumatoid Arthritis Patients from Singapore
XR Lim¹, LZ Liu², X Gao², J W L Tan¹, L W Koh³, TY Lian¹, W Q See⁴, KP Leong¹, ET Koh¹ and TTSH RA Study Group, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ²Clinical Research and Innovation Office, Tan Tock Seng Hospital, Singapore, Singapore, ³Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ⁴Tan Tock Seng Hospital, singapore, Singapore
Background/Purpose: Patients with rheumatoid arthritis (RA) have been shown to have an increased risk of developing malignancies. This study was undertaken to determine the incidence…
Abstract Number: 413 • 2014 ACR/ARHP Annual Meeting
Association of Antinuclear Antibodies with Lung Disease, Malignancy and Joint Replacement in Rheumatoid Arthritis
Reshmi Raveendran¹, Bobby Kwanghoon Han², Quan-Zhen Li³ and Nancy J. Olsen¹, ¹Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ²Rheumatology, Cooper Medical School of Rowan University, Camden, NJ, ³Immunology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose Antinuclear antibodies (ANAs) are present in a significant proportion of patients with rheumatoid arthritis (RA). Positivity for ANA in RA has been associated with…
Abstract Number: 1222 • 2012 ACR/ARHP Annual Meeting
Incidence and Time Trends of Malignancy in Rheumatoid Arthritis: A Population Based Study 1980-2007
Kerry Wright¹, Cynthia S. Crowson², Sherine E. Gabriel³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: to determine the incidence and time trends of malignancy in patients with rheumatoid arthritis (RA) in 1980-2007 compared to individuals without RA from the…
Abstract Number: 1229 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Risks of Malignant Lymphoma – Are Risks Still Increased?
Karin Hellgren¹, Eva Baecklund², Karin E Smedby³, Carin Backlin⁴, Christer Sundstrom⁵ and Johan Askling⁶, ¹Department of Medicine , Karolinska Insitutet at Karolinska University Hospital, Unit of Rheumatology, Stockholm, Sweden, ²Department of Medical Sciences, Rheumatology, Uppsala University Hospital, Uppsala, Sweden, ³Department of Medicine Karolinska Institutet at Karolinska University Hospital, Clinical Epidemiology Unit, Stockholm, Sweden, ⁴Uppsala University, Department of Medical Sciences,, Uppsala, Sweden, ⁵Uppsala University, Department of Genetics and Pathology, Uppsala, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Patients with established Rheumatoid Arthritis (RA) are at increased risk of malignant lymphomas. We have previously demonstrated a strong association between inflammatory intensity and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].